AstraZeneca ADC Barrels Forward as Keytruda Combo Data Make Case for Lung Cancer Use

AstraZeneca and Daiichi Sankyo have delivered more evidence that their TROP2-directed antibody-drug conjugate may have a future in NSCLC, linking the candidate to a roughly 40% overall response rate when used as part of doublet and triplet combination therapies.